Merck & Co. Inc., of Kenilworth, N.J., said the EMA's Committee for Medicinal Products for Human Use adopted a positive opinion recommending approval of Keytruda (pembrolizumab), the company's anti-PD-1 therapy, for the first-line treatment of metastatic non-small-cell lung cancer in adults whose tumors have high PD-L1 expression (tumor proportion score of 50 percent or more) with no EGFR or ALK-positive tumor mutations.